Abstract Details

Title Validation of Pediatric Idiopathic Generalized Epilepsy Diagnoses from the Danish National Patient Register During 1994-2019

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P3 - Poster Session 3 (5:00 PM-6:00 PM)

Poster/Presentation
Number 11-002

Objective

To validate whether pediatric idiopathic generalized epilepsy can be identified in Danish health registers using International Classification of Diseases, 10th Revision (ICD-10) codes combined with anti-seizure prescriptions (1994–2019).

Background The Danish National Patient Register is widely used for epidemiological research, but most validation studies have focused on “any epilepsy” (ICD-10: G40–G41). Whether specific idiopathic generalized epilepsy subtypes can be reliably identified remains uncertain.

Design/Methods We reviewed medical records of children coded with idiopathic generalized epilepsy (ICD-10) before age 18, and pediatric neurologists confirmed diagnoses according to International League Against Epilepsy criteria. We estimated the positive predictive value (PPV) and sensitivity of ICD-10 coding alone, as well as in combination with anti-seizure prescriptions and age at first code registration, using medical record–validated diagnoses as the gold standard.

Results Of 969 children coded with idiopathic generalized epilepsy, 431 were confirmed (115 childhood absence, 97 juvenile absence, 192 juvenile myoclonic, 27 generalized tonic-clonic seizures alone). The PPV of ICD-10 codes combined with an antiseizure prescription and age at registration was 44% for childhood and juvenile absence epilepsy. Adding ethosuximide prescription before age 8 years improved the PPV for childhood absence epilepsy to 59%, but sensitivity remained low (17%). For juvenile myoclonic epilepsy, the highest PPV was 68% (sensitivity 85%) using G40.3F plus antiseizure prescription and age at registration after 8 years. For generalized tonic-clonic seizures alone, the highest PPV was 31% using G40.3G from 2006–2019 plus antiseizure prescription and age at registration after 5 years.

Conclusions

The Danish National Patient Register and the Danish Prescription Database are not reliable for identifying idiopathic generalized epilepsy subtypes in children, except juvenile myoclonic epilepsy, which can be identified with acceptable accuracy but should be interpreted with caution. Without chart review, register data can only identify the broad category of “any epilepsy” (ICD-10: G40–G41) rather than specific idiopathic generalized epilepsy subtypes.

Authors/Disclosures
Magnus Spangsberg Boesen, MD (Herlev Hospital) PRESENTER	Dr. Spangsberg Boesen has nothing to disclose.
Melita Cacic Hribljan (Copenhagen University Hospital, Denmark)	Melita Cacic Hribljan has nothing to disclose.
Soren K. Christensen, MD (Rigshospitalet)	Mr. Christensen has nothing to disclose.
Amalie Klein-Petersen	Miss Klein-Petersen has nothing to disclose.
Sahla El Mahdaoui, MD (Glostrup Hospital)	Dr. El Mahdaoui has received personal compensation in the range of $500-$4,999 for serving as a Speaker's honoraria with Merck.
Malini Sagar (Herlev Hospital)	Malini Sagar has nothing to disclose.
Emilie Schou (Rigshospitalet Glostrup)	Emilie Schou has nothing to disclose.
Anna Eltvedt	Anna Eltvedt has nothing to disclose.
Malene L. Børresen, MD, PhD	Dr. Børresen has nothing to disclose.
Maria Jose Miranda	Maria Jose Miranda has nothing to disclose.
Alfred Peter Born (Rigshospitalet)	Alfred Peter Born has nothing to disclose.
Peter Uldall	Peter Uldall has nothing to disclose.
Lau Thygesen (National Institute of Public Health, University of Southern Denmark)	No disclosure on file

��ɫ��

��ɫ��